Fecal Microbiota Transplantation for Chronic Functional Constipation

NCT ID: NCT03018613

Last Updated: 2017-01-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1/PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-07-31

Study Completion Date

2019-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic functional constipation is a common digestive system disease, the incidence is increasing in recent years.It is reported that the occurrence and development of chronic functional constipation is closely related to imbalance of intestinal flora .Moreover,types and quantity of intestinal flora may be related to intestinal motility. Fecal microbiota transplantation as a new technology to rebuild intestinal flora has been used for several disease,but the clinical efficacy of chronic functional constipation by fecal microbiota transplantation needs to be further explored.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients who meet the inclusion crit chronic functional constipation will be separated into two parts depending on acceptation or refuse of Fecal microbiota transplantation.Blood specimen from patients will be collected to analysis intestinal motility.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Functional Constipation Intestinal Bacteria Flora Disturbance Fecal Microbiota Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

treatment for part 1

Fecal microbiota transplantation and traditional treatments will be used in patients with chronic functional constipation in part 1.

Group Type ACTIVE_COMPARATOR

Fecal Microbiota Transplantation

Intervention Type OTHER

Fecal Microbiota Transplantation and the traditional treatments for chronic functional constipation in part 1.

Placebo for part 2

The traditional treatments and normal saline will be used in patients with chronic functional constipation in part 2 according to associated guidelines.

Group Type PLACEBO_COMPARATOR

Normal Saline

Intervention Type OTHER

Normal saline and the traditional treatments for chronic functional constipation in part 2

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fecal Microbiota Transplantation

Fecal Microbiota Transplantation and the traditional treatments for chronic functional constipation in part 1.

Intervention Type OTHER

Normal Saline

Normal saline and the traditional treatments for chronic functional constipation in part 2

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fecal Microbiota Transplantation(FMT) Normal Saline(NS)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. subjects voluntarily participate in the trial and sign informed consent;
2. sex is not limited,ranging from 18 to 75 years old;
3. meet the diagnostic criteria for chronic functional constipation in patients;
4. patients has been ruled out organic diseases of the large intestine within 1 year by colonoscopy or barium enema examination, and stool routine and occult blood examination are normal within 1 month;
5. be able to communicate well with the researchers and follow the verification requirements.

Exclusion Criteria

1. does not meet the diagnostic criteria;
2. with severe primary heart, liver, lung, kidney, blood or affect the survival of serious diseases;
3. severe anemia and severe systemic infection;
4. suspected or indeed have alcohol, drug abuse history;
5. pregnancy or are preparing for pregnancy, and breastfeeding women;
6. Those who are unwilling to accept the research measures or other reasons can not cooperate;
7. due to mental disorders can not give adequate informed consent;
8. Participated in other clinical trials within 3 months before the start of the study;
9. researchers believe that participates are not suitable for other reasons in this clinical trial.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

First Affiliated Hospital of Chengdu Medical College

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Xiaoan Li, Ph.D

Role: STUDY_CHAIR

First Affiliated Hospital of Chengdu Medical College

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

IEC of Chengdu Medical College

Chendu, , China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Xiaoan Li, Ph.D

Role: CONTACT

+8613880868858

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Xiaoan Li, Ph.D

Role: primary

+8613680868858

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FMT-CFC

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.